Table 1.
Open in new tab

Patients’ characteristics.

PSC-UC [n = 32]UC [n = 34]Controls [n = 36]
Blood samples, n313334
Colonic samples, n12922
Gender, males, n [%]20 [62]19 [56]17 [47]
Age, years median [range]52 [25–75]51 [22–81]62 [26–91]
Small-duct PSC, n [%]4 [12]--
Liver function/biochemistry tests
 ALP, median [range] IU/l221 [117–2947]--
 ALT, median [range] IU/l29.5 [13–182]--
 Bilirubin, median [range] µmol/l9 [5–32]--
 Hyperbilirubinaemia, n [%] > 17 µmol/l7 [22]
 Albumin, median [range] g/l45 [38–49]--
 Platelets, median [range] x 109/l284.5 [167–607]--
 Thrombocytopenia, n [%] < 150*109/l0 [0]
Liver cirrhosis, n [%]1 [3]
IBD duration, years median [range]14 [3–43]9 [0–46]-
IBD extent
 Extensive, n [%]22 [69]9 [26]-
 Left-sided, n [%]318 [53]-
 Proctitis, n [%]0 [0]6 [18]-
Previous colectomy, n [%]7 [22]1 [3]-
UCEIS
 0–2, n87-
 3–5, n42-
 6–8, n00-
Inflammation at histology
 Quiescent, n82-
 Mild to moderate, n47-
 Severe, n00-
Treatment at time of sample collection
 5-aminoslicylates, n [%]20 [62]21 [61]-
 Immunosuppressants, n [%]7 [21]10 [29]-
 Corticosteroids, n [%]2 [6]4 [11]-
 Anti-TNF-α1 [3]4 [11]-
 Anti-integrin therapy, n [%]0 [0]0 [0]-
 Ursodeoxycholic acid23 [72]--
PSC-UC [n = 32]UC [n = 34]Controls [n = 36]
Blood samples, n313334
Colonic samples, n12922
Gender, males, n [%]20 [62]19 [56]17 [47]
Age, years median [range]52 [25–75]51 [22–81]62 [26–91]
Small-duct PSC, n [%]4 [12]--
Liver function/biochemistry tests
 ALP, median [range] IU/l221 [117–2947]--
 ALT, median [range] IU/l29.5 [13–182]--
 Bilirubin, median [range] µmol/l9 [5–32]--
 Hyperbilirubinaemia, n [%] > 17 µmol/l7 [22]
 Albumin, median [range] g/l45 [38–49]--
 Platelets, median [range] x 109/l284.5 [167–607]--
 Thrombocytopenia, n [%] < 150*109/l0 [0]
Liver cirrhosis, n [%]1 [3]
IBD duration, years median [range]14 [3–43]9 [0–46]-
IBD extent
 Extensive, n [%]22 [69]9 [26]-
 Left-sided, n [%]318 [53]-
 Proctitis, n [%]0 [0]6 [18]-
Previous colectomy, n [%]7 [22]1 [3]-
UCEIS
 0–2, n87-
 3–5, n42-
 6–8, n00-
Inflammation at histology
 Quiescent, n82-
 Mild to moderate, n47-
 Severe, n00-
Treatment at time of sample collection
 5-aminoslicylates, n [%]20 [62]21 [61]-
 Immunosuppressants, n [%]7 [21]10 [29]-
 Corticosteroids, n [%]2 [6]4 [11]-
 Anti-TNF-α1 [3]4 [11]-
 Anti-integrin therapy, n [%]0 [0]0 [0]-
 Ursodeoxycholic acid23 [72]--

PSC-UC, primary sclerosing cholangitis-ulcerative colitis; ALP, alkaline phosphatase; ALT, alanine transaminase; IBD, inflammatory bowel disease; UCEIS, Ulcerative Colitis Endoscopic Index of Severity.

Table 1.
Open in new tab

Patients’ characteristics.

PSC-UC [n = 32]UC [n = 34]Controls [n = 36]
Blood samples, n313334
Colonic samples, n12922
Gender, males, n [%]20 [62]19 [56]17 [47]
Age, years median [range]52 [25–75]51 [22–81]62 [26–91]
Small-duct PSC, n [%]4 [12]--
Liver function/biochemistry tests
 ALP, median [range] IU/l221 [117–2947]--
 ALT, median [range] IU/l29.5 [13–182]--
 Bilirubin, median [range] µmol/l9 [5–32]--
 Hyperbilirubinaemia, n [%] > 17 µmol/l7 [22]
 Albumin, median [range] g/l45 [38–49]--
 Platelets, median [range] x 109/l284.5 [167–607]--
 Thrombocytopenia, n [%] < 150*109/l0 [0]
Liver cirrhosis, n [%]1 [3]
IBD duration, years median [range]14 [3–43]9 [0–46]-
IBD extent
 Extensive, n [%]22 [69]9 [26]-
 Left-sided, n [%]318 [53]-
 Proctitis, n [%]0 [0]6 [18]-
Previous colectomy, n [%]7 [22]1 [3]-
UCEIS
 0–2, n87-
 3–5, n42-
 6–8, n00-
Inflammation at histology
 Quiescent, n82-
 Mild to moderate, n47-
 Severe, n00-
Treatment at time of sample collection
 5-aminoslicylates, n [%]20 [62]21 [61]-
 Immunosuppressants, n [%]7 [21]10 [29]-
 Corticosteroids, n [%]2 [6]4 [11]-
 Anti-TNF-α1 [3]4 [11]-
 Anti-integrin therapy, n [%]0 [0]0 [0]-
 Ursodeoxycholic acid23 [72]--
PSC-UC [n = 32]UC [n = 34]Controls [n = 36]
Blood samples, n313334
Colonic samples, n12922
Gender, males, n [%]20 [62]19 [56]17 [47]
Age, years median [range]52 [25–75]51 [22–81]62 [26–91]
Small-duct PSC, n [%]4 [12]--
Liver function/biochemistry tests
 ALP, median [range] IU/l221 [117–2947]--
 ALT, median [range] IU/l29.5 [13–182]--
 Bilirubin, median [range] µmol/l9 [5–32]--
 Hyperbilirubinaemia, n [%] > 17 µmol/l7 [22]
 Albumin, median [range] g/l45 [38–49]--
 Platelets, median [range] x 109/l284.5 [167–607]--
 Thrombocytopenia, n [%] < 150*109/l0 [0]
Liver cirrhosis, n [%]1 [3]
IBD duration, years median [range]14 [3–43]9 [0–46]-
IBD extent
 Extensive, n [%]22 [69]9 [26]-
 Left-sided, n [%]318 [53]-
 Proctitis, n [%]0 [0]6 [18]-
Previous colectomy, n [%]7 [22]1 [3]-
UCEIS
 0–2, n87-
 3–5, n42-
 6–8, n00-
Inflammation at histology
 Quiescent, n82-
 Mild to moderate, n47-
 Severe, n00-
Treatment at time of sample collection
 5-aminoslicylates, n [%]20 [62]21 [61]-
 Immunosuppressants, n [%]7 [21]10 [29]-
 Corticosteroids, n [%]2 [6]4 [11]-
 Anti-TNF-α1 [3]4 [11]-
 Anti-integrin therapy, n [%]0 [0]0 [0]-
 Ursodeoxycholic acid23 [72]--

PSC-UC, primary sclerosing cholangitis-ulcerative colitis; ALP, alkaline phosphatase; ALT, alanine transaminase; IBD, inflammatory bowel disease; UCEIS, Ulcerative Colitis Endoscopic Index of Severity.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close